Omega Diagnostics Share Discussion Threads

[bomber13] 18/4/2019 23:24

A fairly positive Immunodiagnostic trading update for their year to end March appeared after hours today . The Omega component was limited to one sentence , which was nevertheless upbeat , as expected - " We undertook the market launch of our range of IDS branded Allergy assays in March 2019 and expect to see the first sales from this product range during FY2020."

[upomega] 17/4/2019 17:50

Personally happy with the trading update. The board is still delivering on everything that they said they would do after the strategic review. As I posted before my only concern is short term funding. Maybe someone could answer this for me.Is it possible for the company to receive a private loan from an individual hopefully charging less interest than a bank overdraft. If so why have the largest investors bought stock rather than loan funds.
Personally I am not in a position to do this, but there are a number of holders which must be in a position to do this. Its probably due to company law, but I would be interested in peoples views.

[raskal] 17/4/2019 10:25

I am Norti Raskal and reign as King of the castle. To all dirty rascals drowning in my moat I say this:- without ISO 14485 you cannot legally sell product in the EU as there is no CE mark. ISO 13485 is recognised worldwide so both CD4 tests can now be sold where there is mutual recognition.
However some countries keen to develop their own marketing permissions run their own accreditation schemes. Nigeria has a big problem they need to know how well Visitect performs. Experience tells us that results come through in a few months but how bureaucratic the Nigerian authorities are is unknown. Hopefully the directors of Global know the ropes and will cut the mustard. Norti Raskal will enjoy the mustard and roast beef soon now the Indian sacred cow is butchered.

[bomber13] 17/4/2019 09:55

Thanks for the Finncap colour Rivaldo .

Debt at end September was £0.45m , so £0.9m at y/e would not be alarming given the build-out in Food Intolerance and CD4 .

The new 35000 sq ft facility in Food Intolerance should be commissioned in mid 2019 , and underscores the positive outlook for this important segment . The last 4 half-years of sales for FI have now gone £4.13m / £3.42m / £3.84m / £4.21m with the USA recovering from its hiccup and China yet to even start contributing . As you know , Colin King maintains this is a £15m to £20m turnover business within 5 years at excellent margins .

God forbid Buywell is right , but surely the main point is this - at Omega's current market cap of £15m , allergies and CD4 are in for absolutely nothing .

[buywell2] 17/4/2019 09:13

IMO CD4 is going to be a compete write off for ODX

The BOD got it massively wrong in developing a product to sell to struggling 3rd World countries even though it is being priced at peanuts.

IMO CD4 will be written down within 2 years as of now

IMO the only way of raising shareholder value is by putting up the lot for sale now.

dyor
GLA

[gwr7] 17/4/2019 08:51

"The trades Friday are my own selling from IG nominees dealing into my isa poor show on them as the instruction was placed on Tuesday morning . So no sale or purchase before the spiv brigade jump on this."

Are you referring to past and present directors?

[rivaldo] 17/4/2019 08:22

Finncap estimate Food Intolerance to have returned to profit with a £0.4m EBITDA in the last H2. This division alone underpins the current m/cap and prospects look good for the current year.

They expect £0.9m net debt, with £2m available facilities.

Patience is (as ever!) required for CD4, but the potential is large and relatively short-term now rather than being "blue sky", so I'm happy to hold given the core profitable business with CD4 effectively thrown in for free or not very much.

[likitorma] 17/4/2019 07:22

"the adjusted loss before tax (before share-based payments and amortisation of intangible assets) is expected to be £0.3m."

Why not quote the loss taking into account share-based payments and amortisation of intangible assets for transparency?

[likitorma] 17/4/2019 07:14

"the Board is confident that it can bring the Advanced Disease version of this unique test through the ERPD regulatory channel in the current financial year for the benefit of many people living with HIV."

Are you kidding me, current financial year. Most likely nothing happening until Mar 2020 then, because that is when the financial year end. Going by their past performance, this could be delayed further.
Same bs about shareholder value, becoming boring now. They mention it in every RNS but nothing happens.

[hyperboreus] 17/4/2019 07:10

Trading update:



Much as expected from my point of view, no mention of cash balance

'The Board also continues to explore opportunities for realising value for shareholders in line with the Company’s strategic review objectives.' 🤫

[likitorma] 17/4/2019 07:07

Dire trading update. Reckon they will need to raise soon to survive, in my opinion.

[upomega] 13/4/2019 21:46

And also my investments have always been long term.

[upomega] 13/4/2019 21:01

The trades Friday are my own selling from IG nominees dealing into my isa poor show on them as the instruction was placed on Tuesday morning . So no sale or purchase before the spiv brigade jump on this.

[upomega] 13/4/2019 20:30

I Know. I am hoping in allergy and food intollerance to carry cashflow through to cd4200. As I posted before lets see what the trading update provides in forward looking statement , but bills still have to be paid in some format. Its a bit odd actually I get quite excited by shield diagnostics many years ago only to be dissapointed. must be something to do with the diagnostic industry ????????????
INMO. Its how this is now funded over the next twelve months. As you mentioned likoterma [1.3 )percent ) was going to increase but not happy with no news on Nigeriea. For me depends on the fundraise. I wouldn't be surprised to see a convertible and loan note issue geared towards the largest holders and then a sale in two years time.i a may wrong but probably would be dead by then anyway to see the result.

[likitorma] 13/4/2019 19:45

In that case, your 2% will be worth much less, upomega.

[upomega] 13/4/2019 19:39

Alas poor eurack you are burt a noble man. My opinion for what its worth is that omega are wasting their time in marketing cd4350. Its a shame they are not a bigger company and can give this away for free.Maybe in a perfect world this would happen my concern is that they may make and produce thousands of batches and never receive any payment for them.(Shareholder concern)

[raskal] 12/4/2019 09:25

We are the Norti Raskal and King of the castle and reply thus:-

1. Test for HIV if +ve ( like a commercially available pregnacy test)
2. next test to check levels of "Cluster of Differentiation" or CD4.
3. 350 test triggered ny levels of CD4 on T cell receptors HIV uses CD4 to enter host cell and reproduce.
4. 350 Test is available now but the guidlines for commencing treatment have been lowered to the 200 level.
5. Presumably desktop and lab analysers can be simply re calibrated the Visitect CD4 has to be re engineered.

THe Visiect measure does not need an analyser either on a physicians desk or in a pathology laboratory. Nor does it need electricity to work. Its also cheap at the $5.00 level. THe re-agents for the analyser also involve a cost as does the analyser which is either bought or loaned. see this link :- hxxps://www.alere.com/en/home/product-details/PimaAnalyserOUS.html?id=4







So a medical doctor would buy a test for his patients. Think like a clap clinic oooops "Special Clinic"

[upomega] 11/4/2019 18:24

liege

Why would an individual buy the test ?????????.I can understand why clinical technicians would purchase it. maybe I am missing something, but as an individual if I was worried that I may be hiv positive I would have a simple hiv test and then go to the relevant health authority for treatment. Which I would imagine that a cd4 test would be carried out to determine how far my immune system has been effected. This in term would dictate how best to treat me. ONMHO so dyor

[raskal] 11/4/2019 17:39

Norti Raskal reigns as King of the Castle. The Gini cco efficient for Nigeria is 48 i.e. it has tremendous income inequality the top decile control 38% of the countries wealth. With a population approaching 200mm and a median age of 19 years the older part of the population has perhaps 20mm people who match European standards. Since approx 2.9% have HIV approx 1:35 there are perhaps several tens of thousands who might be in the market for a discrete private non lab test at > $20 a pop. 10,000 @ $5.00 is $50,000 and that's against perhaps 20mm people who can afford it. Nigeria has approx 7,000,000 known HIV cases already so if one percent buy the 350 test it's $350,000 or £250,000

[upomega] 11/4/2019 14:07

All very well , but where is the funding going to come from for cd4 350My understanding is that cd4 200 will hopefully be funded by aid agencies.

[raskal] 11/4/2019 12:52

We Norti Raskal KIng of the Castle has the following data on Nigeria:-

HIV/AIDS - adult prevalence rate: This entry gives an estimate of the percentage of adults (aged 15-49) living with HIV/AIDS. The adult prevalence rate is calculated by dividing the estimated number of adults living with HIV/AIDS at yearend by the total adult population at yearend. HIV/AIDS - adult prevalence rate field listing
2.8% (2017 est.)
country HIV/AIDS - adult prevalence rate: This entry gives an estimate of the percentage of adults (aged 15-49) living with HIV/AIDS. The adult prevalence rate is calculated by dividing the estimated number of adults living with HIV/AIDS at yearend by the total adult population at yearend. HIV/AIDS - adult prevalence rate field listing
2.8% (2017 est.)
country comparison to the world: 20
HIV/AIDS - people living with HIV/AIDS: This entry gives an estimate of all people (adults and children) alive at yearend with HIV infection, whether or not they have developed symptoms of AIDS. HIV/AIDS - people living with HIV/AIDS field listing
3.1 million (2017 est.) comparison to the world: 20
HIV/AIDS - people living with HIV/AIDS: This entry gives an estimate of all people (adults and children) alive at yearend with HIV infection, whether or not they have developed symptoms of AIDS. HIV/AIDS - people living with HIV/AIDS field listing
3.1 million (2017 est.)

[upomega] 10/4/2019 21:32

One thought my liege.Omega is dealing with very impoverished countries. CD4 350 is marketed at the commercial market. Even if they do achieve sales they still have to receive payment. Whereas cd4 200 hopefully will be sold through aid agencies.
Maybe investors should be concentrating more on could be achieved with allergens and Food intolerance. ONMHO.

[raskal] 10/4/2019 18:55

I am Norti Raskal and I am still King of the Castle, you are my subjects. Pray why has no one looked up the Nigerian company whose name I released? The directors are on Linkedin.

A trading statement is due there appears a delay in release- so who is managing the information flow? Lastr year the trading statement was released on the 10th April with the strategic review followed by a PRICE MONITORING EXTENSION as the dirty washing was purged. Investor evening on the 19th April followed by the Allersys agreement on the 20th.

Am I the only Norti Raskal or are there pretend Naughty Rascals out there?